Thornton J. Fokkens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thornton J. Fokkens has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Sonja Lorenz
Research Group "Ubiquitin Signaling Specificity", Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany
2 shared publications - Agnieszka Rybak-Wolf
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
1 shared publication - Blanca Baños-Jaime
Research Group "Ubiquitin Signaling Specificity", Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany
1 shared publication Carola Dietrich
Core Unit Genomics, Berlin Institute of Health at Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, 13125 Berlin, Germany
1 shared publication- Claudia Quedenau
Core Unit Genomics, Berlin Institute of Health at Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, 13125 Berlin, Germany
1 shared publication - David Schwefel
Technische Universität Berlin, Chair of Bioanalytics
1 shared publication
Latest Publications
- Open Access
- 9 April 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (6) , 111440
HECT-type ubiquitin ligases: Emerging principles in the era of full-length structures
- 9 April 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (6) , 111440
Open AccessHECT-type ubiquitin ligases: Emerging principles in the era of full-length structures
- Open Access
UBE3C links ubiquitin signaling to epitranscriptomic control of cortical neurogenesis
Neurological conditions are the leading cause of ill health worldwide. Here, we show that the neurodevelopmental disorder-associated ubiquitin ligase UBE3C regulates the cellular composition of the murine cerebral cortex and human brain organoids, with its loss favoring neurogenesis and suppressing glial fate. Using genetic complementation, we demonstrate that disease-associated UBE3C mutations alter its autoubiquitination activity and disrupt cortical lamination. Proteomic profiling of UBE3C -deficient forebrains and organoids identifies Cbll1 as a UBE3C substrate, and we show that the UBE3C-Cbll1 duo drives N 6 -methyladenosine (m6A) mRNA methylation. Hyperactivation of m6A writers in UBE3C -deficient neural progenitors impairs cell cycle exit, a defect reversible in vivo by the METTL3 inhibitor STM2457. Our findings uncover an epiproteomic mechanism controlling m6A-mediated gene expression and define a regulatory axis linking ubiquitin signaling to epitranscriptomic control of neural fate. This work provides a mechanistic framework for understanding neurodevelopmental disorders and highlights potential therapeutic strategies.
Open AccessUBE3C links ubiquitin signaling to epitranscriptomic control of cortical neurogenesis
Neurological conditions are the leading cause of ill health worldwide. Here, we show that the neurodevelopmental disorder-associated ubiquitin ligase UBE3C regulates the cellular composition of the murine cerebral cortex and human brain organoids, with its loss favoring neurogenesis and suppressing glial fate. Using genetic complementation, we demonstrate that disease-associated UBE3C mutations alter its autoubiquitination activity and disrupt cortical lamination. Proteomic profiling of UBE3C -deficient forebrains and organoids identifies Cbll1 as a UBE3C substrate, and we show that the UBE3C-Cbll1 duo drives N 6 -methyladenosine (m6A) mRNA methylation. Hyperactivation of m6A writers in UBE3C -deficient neural progenitors impairs cell cycle exit, a defect reversible in vivo by the METTL3 inhibitor STM2457. Our findings uncover an epiproteomic mechanism controlling m6A-mediated gene expression and define a regulatory axis linking ubiquitin signaling to epitranscriptomic control of neural fate. This work provides a mechanistic framework for understanding neurodevelopmental disorders and highlights potential therapeutic strategies.